Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Rodler

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Urologie (Heidelberg, Germany)|May 26, 2026
[Individualized surgical treatment of benign prostate syndrome]H C von Knobloch, S Rodler, O Weische, et al.
World Journal of Urology|September 4, 2021
Polyethylene glycol-coated collagen patch (hemopatch<sup>®</sup>) in open partial nephrectomyMichael Staehler, S Rodler, M Schott, et al.
Urology|March 16, 2020
Advanced Molecular Imaging in Histologically Verified Metanephric AdenomaL M Mittlmeier, M Unterrainer, A Todica, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 28, 2020
<sup>18</sup>F-PSMA-1007 PET/CT for response assessment in patients with metastatic renal cell carcinoma undergoing tyrosine kinase or checkpoint inhibitor therapy: preliminary resultsL M Mittlmeier, M Unterrainer, S Rodler, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Urologie (Heidelberg, Germany)|May 26, 2026
[Individualized surgical treatment of benign prostate syndrome]H C von Knobloch, S Rodler, O Weische, et al.
World Journal of Urology|September 4, 2021
Polyethylene glycol-coated collagen patch (hemopatch<sup>®</sup>) in open partial nephrectomyMichael Staehler, S Rodler, M Schott, et al.
Urology|March 16, 2020
Advanced Molecular Imaging in Histologically Verified Metanephric AdenomaL M Mittlmeier, M Unterrainer, A Todica, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 28, 2020
<sup>18</sup>F-PSMA-1007 PET/CT for response assessment in patients with metastatic renal cell carcinoma undergoing tyrosine kinase or checkpoint inhibitor therapy: preliminary resultsL M Mittlmeier, M Unterrainer, S Rodler, et al.
Pageof 1